PEPITEM在免疫介导炎症性关节炎中调节滑膜微环境以限制疾病
研究探讨初诊未治疗类风湿关节炎(RA)和银屑病关节炎(PsA)患者脂肪连接蛋白-PEPITEM通路状态,以及PEPITEM在临床前模型中的疗效。患者外周血单核细胞脂肪连接蛋白受体2及APPL-1表达显著降低,PEPITEM治疗在三种动物模型中减轻关节炎严重程度和滑膜炎症。
要点
- 初诊未治疗RA和PsA患者脂肪连接蛋白受体2及APPL-1表达降低,PEPITEM反应减弱。
- PEPITEM治疗在三种炎症性关节炎动物模型中显著减轻关节炎严重程度和关节肿胀。
- PEPITEM抑制环氧化酶2和NF-κB信号通路并改变关节白细胞亚群组成。
核心结论
- 脂肪连接蛋白-PEPITEM通路在RA和PsA中存在失调,PEPITEM治疗在临床前模型中减轻炎症性关节炎。
研究设计与样本
- 研究分析临床疑似关节痛和疑似炎症性关节炎患者外周血,并在三种不同炎症性关节炎动物模型中评估PEPITEM治疗效果。
主要发现
- 初诊RA和PsA患者外周血单核细胞脂肪连接蛋白受体2及下游信号衔接蛋白APPL-1表达显著降低,对脂肪连接蛋白反应减弱且滑膜PEPITEM浓度降低。
- PEPITEM治疗在三种炎症性关节炎动物模型中显著减轻关节炎严重程度、关节肿胀、白细胞浸润和滑膜多种促炎介质(如JE[CCL2]、RANTES、白细胞介素-16)表达。
- PEPITEM治疗抑制环氧化酶2和NF-κB信号通路,并改变招募至关节的白细胞亚群组成。
临床怎么用
- 脂肪连接蛋白-PEPITEM通路可能作为早期免疫介导炎症性疾病治疗干预的潜在靶点,PEPITEM有望作为替代和/或联合治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Here we investigate the status of the adiponectin-PEPITEM pathway in early, treatment naive rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and the therapeutic efficacy of PEPITEM administration in preclinical models. METHODS: Peripheral blood was isolated from patients with clinical suspect arthralgia and suspected inflammatory arthritis and analyzed by flow cytometry or Western blot. Effect of PEPITEM treatment on inflammatory arthritis was assessed in mice by histology, single-cell RNA sequencing, flow cytometry, or multiplex analysis. RESULTS: Patients newly diagnosed with RA and PsA had significantly reduced expression of adiponectin receptor 2 and its downstream signaling adapter protein APPL-1 on their peripheral-blood mononuclear cells, resulting in diminished response to adiponectin and local synovial concentrations of PEPITEM. Building on these observations, treatment with PEPITEM in three distinct inflammatory arthritis animal models significantly reduced arthritis severity, joint swelling, leukocyte infiltration, and expression of several pro-inflammatory mediators (eg, JE [CCL2], RANTES, interleukin-16) in the synovium. Mechanistically, PEPITEM treatment suppressed the cyclooxygenase 2 and NF-κB signaling pathways. Moreover, PEPITEM altered the composition of leukocyte subsets recruited into the joint. CONCLUSION: Collectively, these findings underscore the importance of understanding the dysregulation of the adiponectin-PEPITEM pathway in different immune-mediated inflammatory diseases (IMIDs), such as RA and PsA. The observed differences in expression and downstream signaling through adiponectin receptors suggest potential targets for therapeutic intervention to restore the balance of this regulatory pathway to mitigate chronic inflammation and disease progression in these patients, paving the way for its clinical use as an alternative and/or combination therapy for early IMIDs.
引用
- Wahid M, Kemble S, Abudu O, et al. PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease. Arthritis Rheumatol. 2026. PMID: 41968960. doi:10.1002/art.70108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。